Dear Doctor: This common osteoporosis med increases risk of developing osteonecrosis of the jaw

ANSWER: Denosumab (Prolia) is a treatment for osteoporosis that is normally given as an injection every six months. Among its ...
AOL

Prolia: Is it covered by Medicare?

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...
The Vindicator

TO YOUR GOOD HEALTH: Extraction of tooth can invite risks

I’m a 79-year-old female who’s in good health. I am 5 feet tall and weigh 95 pounds, and I’m very active. I’ve been taking Prolia for the past two to three years for osteoporosis, which has since ...
Drug Store News

Teva’s Prolia biosimilar candidate accepted for review by FDA, EU EMA

Teva shared that the Food and Drug Administration has accepted, and the European Medicines Agency has validated, applications for TVB-009P, a biosimilar candidate to Amgen’s Prolia (denosumab). Both ...
Nasdaq

European Commission Approves Alvotech's AVT03 As A Biosimilar To Prolia And Xgeva

(RTTNews) - Alvotech (ALVO) announced that the European Commission has approved AVT03, a biosimilar to Amgen's Prolia and Xgeva for use across Europe. Prolia is indicated to treat osteoporosis and ...
Monthly Prescribing Reference

FDA Approves Teva’s Prolia Biosimilar Ponlimsi, Accepts Xolair Biosimilar for Review

Clinical data from a phase 3 trial show Ponlimsi has comparable safety and efficacy to Prolia in women with postmenopausal osteoporosis. The Food and Drug Administration (FDA) has approved Ponlimsi ™ ...
Nasdaq

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...